ADC-Focused Myricx Moves To Next Phase With £90m Cash Injection

The UK spin-out from Imperial College London and the Francis Crick Institute has secured a significant series A financing to advance its novel antibody-drug conjugates which it believes offers a highly differentiated profile over standard payload classes.